Format

Send to

Choose Destination
See comment in PubMed Commons below
J Natl Compr Canc Netw. 2014 Jan;12(1):16-9; quiz 19.

Brentuximab vedotin in patients with relapsed HIV-related lymphoma.

Author information

  • 1From Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology & Oncology, Chicago, Illinois.

Abstract

Lymphoma is a well-recognized complication in patients infected with HIV. Although its incidence has declined since the advent of antiretroviral therapy, it remains higher than seen in the general population. Several recent studies have noted improvement in clinical outcomes with the use of modern chemoimmunotherapy regimens. In patients who experience relapse, however, fewer data are available on the role of immunotherapy and its impact on outcomes. This case report presents 2 patients with relapsed HIV-associated lymphoma who experienced a second complete remission after treatment with the immunotherapy agent brentuximab vedotin.

PMID:
24453289
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center